Production of xanthan gum from soybean biodiesel: a preliminary study

Ferreira, Davi da Silva; Costa, Larissa A de Souza; Campos, Márcio Inomata; Bispo, Mozart Daltro; Krause, Laíza Canielas; Hernández-Macedo, María Lucila; López, Jorge A.

doi:10.1186/1753-6561-8-s4-p174

Cited by 2 publications

(1 citation statement)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among the various types of commercially available starch, high-amylose starch has been demonstrated to possess superior properties with regard to drug delivery compared with native starch [5]. Xanthan gum (XG) has also been studied as an ingredient for producing a direct compression matrix with high swelling properties [6,7].…”

Section: Introductionmentioning

confidence: 99%

Coprocessed Excipients of Crosslinked Amylose and Xanthan Gum for Use in Controlled Release Dosage Forms

et al. 2018

View full text Add to dashboard Cite

Objective: This study was aimed to obtain a new excipient that can be used as a polymer matrix for the formulation of controlled release dosage forms. Methods:This study used coprocessing and crosslinking methods on amylose and xanthan gum (XG) to obtain a new excipient that can be used for controlled release matrix of pharmaceutical dosage forms. The coprocessing step was conducted by drum drying, and the crosslinking step was prepared using 6 and 12% sodium trimetaphosphate (STMP). The produced novel excipients were characterized in terms of infrared (IR) spectrum, substitution degree, moisture content, swelling index, and gel strength. Results:Our results showed that amylose-XG excipients crosslinked using 6% STMP have greater gel strength and better swelling indexes than excipients crosslinked using 12% STMP. All coprocessed excipients exhibited no differences in their IR spectra, whereas the crosslinked excipients did, indicating a structural change due to the addition of phosphate groups. Crosslinking amylose-xanthan-coprocessed excipients using 6% STMP produced degrees of substitution (DSs) of 7-8 phosphates per 100 monomeric subunits. The excipients had a moisture content of 8.21-12.85%, and the pH of a 1% solution of excipients was 6.21-6.43. In addition, the swelling index and gel strength of the excipient where both amylose and XG were crosslinked together Were more than 1 where only amylose was crosslinked. Conclusion:The crosslinking amylose-xanthan-coprocessed excipient using 6% STMP is more suitable for use in controlled release dosage forms, particularly when the polymer ratio is 1:1.

show abstract

Section: Introductionmentioning

confidence: 99%